Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Nuvectis Pharma Stock Down 3.0 %

NASDAQ:NVCT opened at $7.36 on Tuesday. Nuvectis Pharma has a 52 week low of $4.44 and a 52 week high of $12.10. The business’s 50-day simple moving average is $6.14 and its two-hundred day simple moving average is $6.40. The stock has a market cap of $142.20 million, a PE ratio of -6.34 and a beta of 0.22.

Insider Activity

In other news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $4.70 per share, with a total value of $79,900.00. Following the transaction, the insider now directly owns 2,612,000 shares in the company, valued at approximately $12,276,400. This trade represents a 0.66 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have acquired 261,500 shares of company stock worth $1,300,825. 35.78% of the stock is currently owned by corporate insiders.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.